Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-01 in Symptomatic Knee Osteoarthritis
NCT07819461Phase 3Not yet recruiting
- Sponsor
- IBSA Group
- Start
- Sep 2026
- Primary completion
- Jun 2027
01
Overview
Phase 3, randomised, double-blind trial of anjianning in osteoarthritis (OA) (2 arms), sponsored by IBSA Group. Primary endpoint: Average Daily Pain Intensity Score at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
anjianning
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07819461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819461.